B
Brickell Biotech Inc
F:VCC2
Brickell Biotech Inc
F:VCC2
Price:
0.1344
EUR
30.61%
Market Closed
Market Cap:
€16m
Relative Value
There is not enough data to reliably calculate the relative value of VCC2.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VCC2
Relative Value
Base Case
Not Available
Multiples Across Competitors
VCC2 Competitors Multiples
Brickell Biotech Inc Competitors
Brickell Biotech Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
B
|
Brickell Biotech Inc
F:VCC2
|
16m EUR | 2.7 | -0.9 | -0.5 | -0.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
396.8B USD | 6.6 | 168.8 | 16.4 | 23.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD | 5.4 | 25.8 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186B USD | 6.4 | 23 | 15.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.7B USD | 10.1 | 32.3 | 23.7 | 24.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.6B USD | 5.6 | 17.9 | 15.2 | 17.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
89B AUD | 4 | 20.6 | 13.8 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR | 14.3 | 33.7 | 57.5 | 59.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
